Genentech's (RHHBY) Lucentis Receives FDA Approval for Wet AMD

FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Lucentis prefilled syringe offers a ready-to-use option to deliver treatment with fewer steps First anti-VEGF prefilled syringe FDA-approved to treat people with wet age-related macular degeneration and people with macular edema after retinal vein occlusion

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis® (ranibizumab injection) 0.5 mg prefilled syringe (PFS) as a new method of... More